ArticleDiscover oncology2025
A phase separation-related gene signature for prognosis prediction and immunotherapy response evaluation in gastric cancer with targeted natural compound discovery.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundAberrant phase separation (PS) has emerged as a pivotal pathogenic mechanism in cancer development. However, its prognostic significance and influence on the tumor immune microenvironment in gastric cancer (GC) remain largely unexplored. This study aimed to develop a PS-related risk model for predicting clinical outcomes and immunotherapy response, and to identify potential natural small-molecule compounds targeting proteins within this PS-related network.
methodsWe integrated transcriptomic data from the TCGA-STAD and GSE62254 datasets with four PS-related databases (including DrLLPS, PhaSepDB, PhaSePro, and LLPSDB) to identify candidate signature genes. The prognostic model was developed using least absolute shrinkage and selection operator (LASSO) regression and validated in both cohorts. Immune checkpoint inhibitor (ICI) response between PS-related high- and low-risk groups was evaluated using TIDE algorithm scores. Potential therapeutic agents targeting signature genes were screened via Connectivity Map and HERB database analyses, followed by molecular docking validation.
resultsBy Integrating analysis of the differential expression dataset from TCGA-STAD (n = 407, 375 tumor/32 normal) with prognosis-related dataset and PS-related dataset, we identified 78 candidate genes and developed a robust 21-gene risk prediction model. The model effectively stratified GC patients into high-risk and low-risk subgroups, with consistent performance in the independent GSE62254 validation cohort (n = 300, tumor). Compared to low-risk patients, high-risk patients exhibited poorer survival, a more immunosuppressive microenvironment, and a reduced response to immunotherapy. Moreover, computational screening identified 18 potential therapeutic natural compounds, 13 of which showed high-affinity binding to signature genes (docking scores > 6.0).
conclusionsOur study developed a novel PS-related risk model that predicts GC outcomes, characterizes tumor immune microenvironment, evaluates immunotherapy response, and identifies targeting small molecules. These findings advance the understanding of PS regulation in GC and provide a framework for personalized therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.